JOHNS HOPKINS MEDICINE

ABOUT JOHNS HOPKINS MEDICINE

HEALTH INFORMATION

PATIENT CARE

RESEARCH

EDUCATION

WHAT'S NEW
Web notes  
October 2004
LICENSING AND TECHNOLOGY DEVELOPMENT- Back

LICENSING & TECHNOLOGY DEVELOPMENT

Corporate MTAs: Panacea or Boondoggle?

For the researcher, the principal questions are always where and from whom can I get the Materials to do the science? Where the provider of the Materials is a corporate for-profit entity, the melding of an agreement reflective of two very different entities and their respective missions can be challenging and time-consuming.

The Panacea:
Materials Transfer Agreements, or "MTAs" arose as a result of folks attempting to facilitate academic use of collective and individual scientific resources. Whether publicly or privately developed, those resources, when readily and easily exchanged, could mean the arriving at the finish line with inventions or discoveries sooner rather than later. If we could all just "get along," the MTA could become the Panacea.

One must ask: What does "getting along" entail?

Now, the Boondoggle:
More often than not companies seem to exist in a state of denial. While they attest to an understanding of the constraints of the scientist operating within a not-for-profit academic institution, they more often than not put us to the test. What's the test? How badly do you want or need the Materials? They will challenge our resolve in the following ways, to name a few:

  • Proper Parties: Sending the MTA in the name of the scientist. (JHU is the proper party, not the scientist.)
  • Publication Restrictions: Requiring open delays and consent by the company prior to publication violates this and most every university's mission and policies.
  • Defining the Materials: Often the company defines the Materials to include the scientist's discoveries, data, indeed, any information generated in the course of the research under the MTA.
  • Licenses: The MTA is reconfigured before your very eyes from a simple transfer of materials to a broad royalty-free commercial license to any invention or discovery related to the research! Great caution must be exercised to assure that these rights do not conflict with or supersede the rights of the sponsor under whose funding the research is conducted.

Conclusion:
Ask Yourself:

  1. Asking the company to 'walk the walk': Early intervention into a company's state of denial may speed things along. A reminder of our status as a not-for-profit university sometimes gets some attention. (Usually the mere mention of the taxation authorities gets some well-deserved attention!)
  2. "How badly do you want or need the Materials?" Also, communicating to our MTA negotiator as to how these Materials figure into a research project, including whether they are unique or otherwise unavailable except under the MTA, allows the negotiator to 'work smart' in achieving closure on the agreement.
  3. "Is the scale careening in favor of the for-profit interest?" Assessing the true value of the Materials in the research is key to achieving a reasonable balance between the University's and the company's interests. Ask whether or not the rights conferred under the MTA are truly proportionate to the company's contribution. This can be a very valuable exercise. Remember, it is your expertise and university facilities that contribute to any fruits of the research.

In summary, the Association of University Technology Managers (AUTM) has addressed the significant obligation of a non-profit research institution to ensure that the public benefits from its research. Achieving reasonable compromise between the vastly differing missions of the not-for-profit and the for-profit in the context of that urgent MTA can be quite a challenge!

For more information please contact:
Julia M. Brill
Copyright and Material Transfer Officer
Licensing and Technology Development
410 516-4971
jbrill7@jhmi.edu


Return to top of Licensing and Technology Development

 
   
October 2004 articles:

New Diet for Research Animals
Important Reminders
Seminar Series
Corporate MTAs: Panacea or Boondoggle?

NIH Model Organism Sharing Policy
New eIS Goes Live November 2, 2004
SOM to Launch eSNAP - January 2005
NIH Loan Repayment Programs - Now Accepting Applications
New Rate Agreement for Indirect Costs and Fringe Benefits
New Office of Research Administration (ORA) Contact List and Departmental Assignments
Clinician Scientist Career Development Awards
Research Patient Care Rates for Clinical Trials
NIH Announces New Address for Centralized Receipt of Progress Reports Due On/After October 1, 2004

This Month's Departmental Listings
       

 

JHM AppointmentsEmployment @ JHM | Finding a Doctor | FAQs | Disclaimer | Maps & Directions | Contact JHM | Site Map

 

                                                                                                                                                           The Web Center